Relapsing polychondritis

Bruce A. Staats, James P Utz, Clement Michet

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Relapsing polychondritis (RP) is a rare disease causing inflammation and destruction of cartilage and other connective tissues. Specific laboratory aberrations are lacking. Predominant clinical manifestations include auricular chondritis, polyarthritis, nasal chondritis, ocular inflammation, audiovestibular damage, and respiratory tract chondritis. A relapsing course is characteristic. Airways are involved in 50% of patients and may cause dyspnea, stridor, wheezing, hoarseness, aphonia, and laryneal or tracheal tenderness. Airflow obstruction may result from RP involving the tracheobronchial tree; there is no interstitial or pulmonary vascular component. Collapse or failure of the trachea to dilate during inspiration is a key feature. Fast computed tomographic (CT) scanners can visualize dynamic airway collapse. Randomized, controlled trials of therapy have not been done. Corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs) are used most commonly, but optimal regimens and duration of therapy have not been elucidated. Endobronchial stents or tracheostomy may be required for severe stenoses refractory to medical therapy.

Original languageEnglish (US)
Pages (from-to)145-154
Number of pages10
JournalSeminars in Respiratory and Critical Care Medicine
Volume23
Issue number2
DOIs
StatePublished - 2002

Fingerprint

Relapsing Polychondritis
Respiratory Sounds
Aphonia
Inflammation
Hoarseness
Tracheostomy
Rare Diseases
Trachea
Nose
Respiratory System
Connective Tissue
Dyspnea
Arthritis
Cartilage
Stents
Blood Vessels
Adrenal Cortex Hormones
Pathologic Constriction
Anti-Inflammatory Agents
Therapeutics

Keywords

  • Airway collapse
  • Cartilage
  • Chondritis
  • Relapsing polychondritis
  • Tracheal stenosis

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine
  • Pulmonary and Respiratory Medicine
  • Critical Care

Cite this

Relapsing polychondritis. / Staats, Bruce A.; Utz, James P; Michet, Clement.

In: Seminars in Respiratory and Critical Care Medicine, Vol. 23, No. 2, 2002, p. 145-154.

Research output: Contribution to journalArticle

@article{a2924e21274a4776968517121f2da31d,
title = "Relapsing polychondritis",
abstract = "Relapsing polychondritis (RP) is a rare disease causing inflammation and destruction of cartilage and other connective tissues. Specific laboratory aberrations are lacking. Predominant clinical manifestations include auricular chondritis, polyarthritis, nasal chondritis, ocular inflammation, audiovestibular damage, and respiratory tract chondritis. A relapsing course is characteristic. Airways are involved in 50{\%} of patients and may cause dyspnea, stridor, wheezing, hoarseness, aphonia, and laryneal or tracheal tenderness. Airflow obstruction may result from RP involving the tracheobronchial tree; there is no interstitial or pulmonary vascular component. Collapse or failure of the trachea to dilate during inspiration is a key feature. Fast computed tomographic (CT) scanners can visualize dynamic airway collapse. Randomized, controlled trials of therapy have not been done. Corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs) are used most commonly, but optimal regimens and duration of therapy have not been elucidated. Endobronchial stents or tracheostomy may be required for severe stenoses refractory to medical therapy.",
keywords = "Airway collapse, Cartilage, Chondritis, Relapsing polychondritis, Tracheal stenosis",
author = "Staats, {Bruce A.} and Utz, {James P} and Clement Michet",
year = "2002",
doi = "10.1055/s-2002-25303",
language = "English (US)",
volume = "23",
pages = "145--154",
journal = "Seminars in Respiratory and Critical Care Medicine",
issn = "1069-3424",
publisher = "Thieme Medical Publishers",
number = "2",

}

TY - JOUR

T1 - Relapsing polychondritis

AU - Staats, Bruce A.

AU - Utz, James P

AU - Michet, Clement

PY - 2002

Y1 - 2002

N2 - Relapsing polychondritis (RP) is a rare disease causing inflammation and destruction of cartilage and other connective tissues. Specific laboratory aberrations are lacking. Predominant clinical manifestations include auricular chondritis, polyarthritis, nasal chondritis, ocular inflammation, audiovestibular damage, and respiratory tract chondritis. A relapsing course is characteristic. Airways are involved in 50% of patients and may cause dyspnea, stridor, wheezing, hoarseness, aphonia, and laryneal or tracheal tenderness. Airflow obstruction may result from RP involving the tracheobronchial tree; there is no interstitial or pulmonary vascular component. Collapse or failure of the trachea to dilate during inspiration is a key feature. Fast computed tomographic (CT) scanners can visualize dynamic airway collapse. Randomized, controlled trials of therapy have not been done. Corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs) are used most commonly, but optimal regimens and duration of therapy have not been elucidated. Endobronchial stents or tracheostomy may be required for severe stenoses refractory to medical therapy.

AB - Relapsing polychondritis (RP) is a rare disease causing inflammation and destruction of cartilage and other connective tissues. Specific laboratory aberrations are lacking. Predominant clinical manifestations include auricular chondritis, polyarthritis, nasal chondritis, ocular inflammation, audiovestibular damage, and respiratory tract chondritis. A relapsing course is characteristic. Airways are involved in 50% of patients and may cause dyspnea, stridor, wheezing, hoarseness, aphonia, and laryneal or tracheal tenderness. Airflow obstruction may result from RP involving the tracheobronchial tree; there is no interstitial or pulmonary vascular component. Collapse or failure of the trachea to dilate during inspiration is a key feature. Fast computed tomographic (CT) scanners can visualize dynamic airway collapse. Randomized, controlled trials of therapy have not been done. Corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs) are used most commonly, but optimal regimens and duration of therapy have not been elucidated. Endobronchial stents or tracheostomy may be required for severe stenoses refractory to medical therapy.

KW - Airway collapse

KW - Cartilage

KW - Chondritis

KW - Relapsing polychondritis

KW - Tracheal stenosis

UR - http://www.scopus.com/inward/record.url?scp=0036225972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036225972&partnerID=8YFLogxK

U2 - 10.1055/s-2002-25303

DO - 10.1055/s-2002-25303

M3 - Article

C2 - 16088607

AN - SCOPUS:0036225972

VL - 23

SP - 145

EP - 154

JO - Seminars in Respiratory and Critical Care Medicine

JF - Seminars in Respiratory and Critical Care Medicine

SN - 1069-3424

IS - 2

ER -